![]() | |
Company type | Public |
---|---|
Headquarters | Rancho Cucamonga, California, United States |
Key people |
|
Revenue | ![]() |
![]() | |
![]() | |
Total assets | ![]() |
Total equity | ![]() |
Number of employees | 1,615 |
Website | Amphastar.com |
Footnotes / references [1] [2] [3] |
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. [4] It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. [5]
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. [6] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. [6]
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. [7]
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. [8] [9]
![]() | |
Company type | Public |
---|---|
Headquarters | Rancho Cucamonga, California, United States |
Key people |
|
Revenue | ![]() |
![]() | |
![]() | |
Total assets | ![]() |
Total equity | ![]() |
Number of employees | 1,615 |
Website | Amphastar.com |
Footnotes / references [1] [2] [3] |
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. [4] It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. [5]
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. [6] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. [6]
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. [7]
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. [8] [9]